CD27 and neoplasm: As DC have the capacity to be loaded with antigens for therapeutic vaccination, the combination of antigen-loaded DC (Figure 1) enhanced with CD27 stimulating mAbs could have applications as a vehicle to enhance anti-tumor responses to defined tumor neo-antigens by exploiting the effects of the CD27 pathway on T cell priming.